Studies of the antagonist actions of (RS)-2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazoly]propionic acid (ATPO) on non-NMDA receptors in cultured rat neurones

被引:3
作者
Dai, WM
Ebert, B
Madsen, U
Lambert, JDC [1 ]
机构
[1] Univ Aarhus, Dept Physiol, DK-8000 Aarhus C, Denmark
[2] Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen, Denmark
[3] Royal Danish Sch Pharm, Dept Med Chem, DK-2100 Copenhagen O, Denmark
关键词
AMPA; kainate; (2S; 4R)-4-methylglutamic acid; (RS)-2-amino-3-5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]-propionic acid (ATPO); cultured neurones; cyclothiazide; concanavalin A; GYKI; 53655;
D O I
10.1038/sj.bjp.0702236
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Whole-cell patch-clamp recordings from single cultured cortical neurones have been used to study the action of (RS)-2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid (ATPO), which has previously been proposed to be a potent selective antagonist of 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptors. 2 ATPO competitively reduced peak responses evoked by semi-rapid applications of AMPA (K-i=16 mu M) but had variable effects on plateau responses, which were on average unchanged. Following blockade of AMPA receptor desensitization by cyclothiazide (CTZ, 100 mu M), the plateau responses were reduced by ATPO to a similar extent as the peak responses, indicating that ATPO reduces desensitization of AMPA receptors. 3 Semi-rapid application of kainic acid (KA) and the KA receptor-selective agonist, (2S,4R)-4-methylglutamic acid (MeGlu) evoked non-desensitizing responses which were competitively antagonized by ATPO (Ki values: 27 and 23 mu M, respectively). 4 Responses to MeGlu were unaffected by CTZ (100 mu M), but potentiated 3 fold following blockade of KA receptor desensitization by concanavalin A (Con A, 300 mu g ml(-1)). Responses of spinal cord neurones to MeGlu were blocked by ATPO to a similar extent before and after blockade of KA receptor desensitization by Con A. 5 Although selectively potentiated by Con A, plateau responses to MeGlu were reduced by 69.6% by the AMPA selective antagonist, GYKI 53655 (10 mu M). The remaining component was further reduced by ATPO with a K-i of 36 mu M, which was not significantly different from that in the absence of GYKI 53655, but was greater than that on responses to AMPA. 6 It is concluded that ATPO is a moderate-potency competitive inhibitor of naturally expressed non-NMDA receptors.
引用
收藏
页码:1517 / 1528
页数:12
相关论文
共 54 条
[1]  
[Anonymous], DRUG NEWS PERSPECT
[2]   Functional and molecular analysis of glutamate-gated channels by patch-clamp and RT-PCR at the single cell level [J].
Audinat, E ;
Lambolez, B ;
Rossier, J .
NEUROCHEMISTRY INTERNATIONAL, 1996, 28 (02) :119-136
[3]   NEUROTRANSMITTER RECEPTORS .2. AMPA AND KAINATE RECEPTORS [J].
BETTLER, B ;
MULLE, C .
NEUROPHARMACOLOGY, 1995, 34 (02) :123-139
[4]   CLONING OF A PUTATIVE GLUTAMATE RECEPTOR - A LOW AFFINITY KAINATE-BINDING SUBUNIT [J].
BETTLER, B ;
EGEBJERG, J ;
SHARMA, G ;
PECHT, G ;
HERMANSBORGMEYER, I ;
MOLL, C ;
STEVENS, CF ;
HEINEMANN, S .
NEURON, 1992, 8 (02) :257-265
[5]   Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: Stereospecificity and selectivity profiles [J].
Bleakman, D ;
Ballyk, BA ;
Schoepp, DD ;
Palmer, AJ ;
Bath, CP ;
Sharpe, EF ;
Woolley, ML ;
Bufton, HR ;
Kamboj, RK ;
Tarnawa, I ;
Lodge, D .
NEUROPHARMACOLOGY, 1996, 35 (12) :1689-1702
[6]   A SYNAPTIC MODEL OF MEMORY - LONG-TERM POTENTIATION IN THE HIPPOCAMPUS [J].
BLISS, TVP ;
COLLINGRIDGE, GL .
NATURE, 1993, 361 (6407) :31-39
[7]   SURVIVAL AND GROWTH OF HIPPOCAMPAL-NEURONS IN DEFINED MEDIUM AT LOW-DENSITY - ADVANTAGES OF A SANDWICH CULTURE TECHNIQUE OR LOW OXYGEN [J].
BREWER, GJ ;
COTMAN, CW .
BRAIN RESEARCH, 1989, 494 (01) :65-74
[8]   EXCITOTOXIC CELL-DEATH [J].
CHOI, DW .
JOURNAL OF NEUROBIOLOGY, 1992, 23 (09) :1261-1276
[9]   A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission [J].
Clarke, VRJ ;
Ballyk, BA ;
Hoo, KH ;
Mandelzys, A ;
Pellizzari, A ;
Bath, CP ;
Thomas, J ;
Sharpe, EF ;
Davies, CH ;
Ornstein, PL ;
Schoepp, DD ;
Kamboj, RK ;
Collingridge, GL ;
Lodge, D ;
Bleakman, D .
NATURE, 1997, 389 (6651) :599-603
[10]  
Dai WM, 1997, BRIT J PHARMACOL, V122, pP61